Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

Introduction Measurable (or minimal) residual disease (MRD) refers to any laboratory test that measures the response of a patient's malignancy to cytotoxic chemotherapy. For decades, complete ...

Illumina, Inc. ILMN recently entered into an agreement with Janssen Research & Development, LLC (Janssen) to develop its novel molecular residual disease (MRD) assay. The assay is a multi-cancer whole ...

Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma AUSTIN, Texas--(BUSINESS WIRE)--Natera, ...

Add Yahoo as a preferred source to see more of our stories on Google. New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in multiple myeloma by guiding personalized treatment intensity, potentially ...

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation. It's been more than 20 years since ...

The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...

DUBLIN--(BUSINESS WIRE)--The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been ...

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...